This review aims to provide a translational perspective on recent developments in heart
failure with preserved ejection fraction (HFpEF), linking mechanistic insights to potential …

Heart failure (HF) is growing to a modern epidemic and despite advances in therapy, it still
carries an ominous prognosis and a significant socioeconomic burden. 1 Many novel agents …

Serum biomarkers are an important tool in the baseline risk assessment and diagnosis of
cardiovascular disease in cancer patients receiving cardiotoxic cancer treatments. Increases …

Since the late 1990s, there has been a steady decline in cancer-related mortality, in part
related to the introduction of so-called targeted therapies. Intended to interfere with a specific …

The heart is a complex organ consisting of various cell types, each of which plays an
important role in both physiological and pathophysiological conditions. The cells …

The heart is a highly structured organ consisting of different cell types, including myocytes,
endothelial cells, fibroblasts, stem cells, and inflammatory cells. This pluricellularity provides …

Heart failure with preserved ejection fraction (HFpEF) is one of the largest unmet clinical
needs in 21st-century cardiology. It is a complex disorder resulting from the influence of …

The clinical use of doxorubicin in cancer is limited by cardiotoxic effects that can lead to
heart failure. Whereas earlier work focused on the direct impact of doxorubicin on …

Pregnancy is commonly referred to as a window into future CVH (cardiovascular health).
During pregnancy, physiological adaptations occur to promote the optimal growth and …

Antineoplastic drugs can be associated with several side effects, including cardiovascular
toxicity (CTX). Biochemical studies have identified multiple mechanisms of CTX …